BrainsWay to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

Rhea-AI Summary

BrainsWay Ltd. (NASDAQ: BWAY) will announce its fourth quarter and full year 2020 financial results on March 24, 2021, after market close. A conference call to discuss these results and provide business updates is scheduled for March 25, 2021, at 8:30 AM ET. The call can be accessed via phone or webcast, with replay available for 30 days post-event. BrainsWay is recognized for its non-invasive Deep Transcranial Magnetic Stimulation technology, FDA-approved for various disorders including major depressive disorder and obsessive-compulsive disorder.

Positive

• Upcoming release of Q4 and FY 2020 financial results may provide insights into financial health.
• Hosting a conference call and webcast indicates transparency with investors.

Negative

• None.

CRESSKILL, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its fourth quarter and full year 2020 financial results as well as operational highlights after the close of the financial markets on Wednesday, March 24, 2021. The Company will host a conference call and webcast on Thursday, March 25, 2021 at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date:	Thursday, March 25, 2021
Time:	8:30 AM Eastern Time
United States:	877-407-3982
Israel:	1 809 406 247
International:	201-493-6780
Conference ID:	13717245
Webcast:	http://public.viavid.com/index.php?id=143838

The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/events-and-presentations/event-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. To learn more, please visit www.brainsway.com

Contacts: 
BrainsWay:
Hadar Levy
SVP and General Manager
HadarL@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will BrainsWay report its Q4 and full year 2020 financial results?

BrainsWay will report its Q4 and full year 2020 financial results on March 24, 2021, after market close.

What time is the BrainsWay conference call?

The BrainsWay conference call is scheduled for March 25, 2021, at 8:30 AM Eastern Time.

How can I access the BrainsWay conference call?

The conference call can be accessed via telephone or through a webcast available on the Company's website.

What technology is BrainsWay known for?

BrainsWay is known for its non-invasive Deep Transcranial Magnetic Stimulation platform technology used for treating brain disorders.

Which disorders has BrainsWay's technology received FDA approval for?

BrainsWay's technology has received FDA approval for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.